EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancing Gene Therapy for Phenylketonuria: From Precision Editing to Clinical Translation

Inseon Yu iD, Jaemin Jeong iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178722 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Inseon Yu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biohealth Convergence, College of Science and Convergence Technology, Seoul Women's University, Seoul 01797, Republic of Korea. Hauptthemen laut MEDLINE: Phenylketonurias, Genetic Therapy, Gene Editing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Seoul Women's University, Genome editing research program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phenylketonuria (PKU) is an inherited disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene that result in the amino acid phenylalanine (Phe) building up in the blood. Current therapies suggest low-Phe dietary management and (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) therapy, which are limited in efficacy and require lifelong treatment. Recent advances in gene therapy, including gene editing and viral-mediated gene delivery, produce therapeutic effects. Advancements in gene editing technologies, notably adenine base editors (ABEs) and CRISPR-based systems, in conjunction with enhanced delivery methods such as lipid nanoparticles (LNPs) and recombinant viruses, have demonstrated substantial promise in preclinical studies. This review details the pathophysiology of PKU treatment, and progress in preclinical and clinical gene therapy strategies. Emphasis is on adenine base editing using LNPs, recombinant adeno-associated virus (rAAV)-mediated gene transfer, and the translational challenges associated with these technologies. We also discuss future directions for therapeutic reach and ensuring long-term safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylketonuriasGenetic TherapyGene EditingHumansAnimalsCRISPR-Cas SystemsPhenylalanine HydroxylaseGene Transfer TechniquesDependovirusTranslational Research, BiomedicalNanoparticles

Stichwörter der Autor:innen

Phenylketonuria (PKU)adeno-associated virusanimal modelbase editinggene therapy

Substanzen

Phenylalanine Hydroxylase

Autor:innen und Institutionen

  • Department of Biohealth Convergence, College of Science and Convergence Technology, Seoul Women's University, Seoul 01797, Republic of Korea.

ORCID-Profile: Inseon Yu, Jaemin Jeong

Förderung

  • National Research Foundation of Korea
  • Seoul Women's University
  • Genome editing research program
  • Korea government (MSIT)
  • Seoul Women’s University

Zitieren

APA

Yu, I., & Jeong, J. (2025). Advancing Gene Therapy for Phenylketonuria: From Precision Editing to Clinical Translation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178722

Vancouver

Yu I, Jeong J. Advancing Gene Therapy for Phenylketonuria: From Precision Editing to Clinical Translation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178722

BibTeX
@article{Yu2025,
  author = {Yu, Inseon and Jeong, Jaemin},
  title = {Advancing Gene Therapy for Phenylketonuria: From Precision Editing to Clinical Translation},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178722}
}
Kostenlos starten →